Abstract
Summary
The aims of therapy with antipsychotic medications include effecti ve relief of symptoms without the induction of adverse effects, improved quality of life and cost effectiveness, and positive long term outcomes. However, currently available anti psychotics do not meet all of these requirements due to a number of well recognised limitations, such as a marked variability of response, induction of a wide range of adverse effects and a lack of subjective tolerability.
A lack of response to antipsychotic medications occurs in up to 30% of patients and poses a particular challenge to clinicians. The reintroduction of clozapine for the treatment of patients with refractory schizophrenia has proven useful in a good number of patients, albeit with some risk of serious agranulocytosis and at a relatively high cost.
Despite the extensive use of anti psychotics over the last 4 decades, little attention has been paid to the systematic evaluation of quality of life in patients with schizophrenia who receive medications, and in clinical trials of new agents. Similarly, there is a dearth of studies that have examined the cost effectiveness and cost utility of anti psychotics in terms of quality of life.
In general, the aim of anti psychotics of alleviating psychotic symptoms without negatively affecting the functional status of patients has not been adequately, nor consistently, achieved with currently available agents. However, with the recent acceleration in the development of new antipsychotics, it is hoped that new drugs will soon be available which will prove to be more effective in treating more symptoms of schizophrenia and will be associated with fewer, or ideally no, adverse effects.
Similar content being viewed by others
References
Davies LM, Drummond ME. The economic burden of schizophrenia. Psychiatr Bull 1990; 14: 522–5
Gunderson JG, Mosher LR. The cost of schizophrenia. Am J Psychiatry 1975; 132: 901–6
Wyatt RJ. Cost and savings in schizophrenia. Presentation to the Third Workshop on Cost and Assessment in Psychiatry; 1994 Oct 28-30; Venice,Italy
Cole JO, Goldberg SC, Klerman GL. Phenothiazine treatment in acute schizophrenia. Arch Gen Psychiatry 1964; 10: 246–61
Goldberg SC, Klerman GL, Cole JO. Changes in schizophrenic psychopathology and ward behaviour as a function of phenothiazine treatment. Br J Psychiatry 1965 111; 120–3
Cole JO, Klerman GL, Davies JM. Drugs in the treatment of psychosis in controlled studies. In: Solomon P, editor. Psychiatric drugs. New York: Grune and Stratton, 1966: 153–80
Davis JM, Schaffer CB, Killman GA, et al. Important issues in the treatment of schizophrenia. Schizophr Bull 1980; 6: 70–87
Davis JM. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Am J Psychiatry 1975; 132: 1237–45
Leff JP, Wing JK. Trial maintenance therapy in schizophrenia. BMJ 1971; 2: 599–603
Prien RF, Levine J, Switalsky RN. Discontinuation of chemotherapy for chronic schizophrenics. Hosp Community Psychiatry 1977; 22: 4–9
Awad AG. Drug therapy in schizophrenia — variability of outcome and prediction of response. Can J Psychiatry 1989; 34: 711–20
Judd LL, Goldstein MJ, Rodnick EH, et al. Phenothiazine effects in good premorbid schizophrenics divided into paranoid- non paranoid status. Arch Gen Psychiatry 1973; 29: 207–11
Rappaport M, Hopkins KH, Hall K, et al. Are there schizophrenics for whom drugs may be unnecessary or contraindicated? Int Pharmacopsychiatry 1987; 13: 100–11
May PRA, Goldberg Sc. Prediction of schizophrenic patients’ response to pharmacotherapy. In: Lipton MA, Di Mascio A, Killam KF, editors. Psychopharmacology: a generation of progress. New York: Raven Press, 1978: 1135–9
Lydiard BR, Laird LK. Prediction of response to anti psychotics. J Clin Psychopharmacol 1988; 8: 3–13
Stern RG, Kahn RS, Davidson M. Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am 1993; 16: 313–38
Awad AG. Prediction research of neuroleptic treatment outcome in schizophrenia — state of the art: 1978-1993. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia - concepts and methods. Vienna: Springer-Verlag, 1994: 1–4
Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenics. Arch Gen Psychiatry 1988; 45: 789–96
Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. J Clin Psychiatry 1989; 50: 329–38
Awad AG. There are real risks and benefits with clozapine in schizophrenia. Med North Am 1992; 4: 234–8
Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophrenia Bull 1993; 19: 609–18
Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1978; 38: 187–90
Hogan TP, Awad AG, Eastwood MR. Self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative ability. Psychol Med 1983; 13: 177–83
Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992; 22: 347–52
Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand 1994; 89 Suppl. 380: 27–32
Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992; 3: 261–5
Awad AG. Quality of life in medicated schizophrenics: therapeutic and research implications. In: Shriqui C, Nasrallah H, editors. Contemporary issues in the treatment of schizophrenia. Washington: American Psychiatric Association Press, 1995: 883–46
Voruganti LNP, Heslegrave R, Awad AG. Schizophrenia, antipsychotic therapy and quality of life — validation of a conceptual model. Presentation to 33rd Annual Meeting of the American College of Neuropsychopharmacology; 1994 Dec 12-16
Schipper H, Clinch J, Powell V. Definition and conceptual issues. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press, 1990: 11–24
Davidhizar RE. Can clients with schizophrenia describe feelings and beliefs about taking medications. J Adv Nursing 1985; 10: 469–73
Awad AG. Quality of life on neuroleptics - implications for health economics and drug trials in schizophrenia. Presentation to the Third Workshop on Cost and Assessment in Psychiatry; 1994 Oct 28-30; Venice
Skantze K, Maim U, Decker SJ, et al. Comparison of quality of life with standard of living in schizophrenia out-patients. Br J Psychiatry 1992; 161: 797–801
Fitton A, Benfield P. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. PharmacoEconomics 1993; 4: 131–56
Kane JM, Lieberman JA. Maintenance pharmacotherapy in schizophrenia. In: Meltzer H, editor. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987: 1103–9
Glick ID. Neuroleptic psychosocial interactions and prediction of outcome. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia. Vienna: Springer-Verlag, 1994: 65–70
Glick ID, Spencer JH, Clarkin JF, et al. A randomized clinical trial of impatient family intervention: IV. Follow-up results for subjects with schizophrenia. Schizophr Res 1990; 3: 187–200
Schooler NR, Keith SJ, Severe JB, et al. Acute treatment response and short-term outcome in schizophrenia in first results of NIMH treatment strategies in schizophrenia study. Psychopharmacol Bull 1989; 25: 331–5
Herz MI.Intermittent medication and schizophrenia. In: Kane JM, editor. Drug maintenance strategies in schizophrenia. Washington: American Psychiatric Association, 1984: 58–68
Carpenter WT, Heinricks OW, Hanlan TE. A comparative trial of pharmacologic strategies in schizophrenia. Am J Psychiatry 1987; 144: 1466–70
Gaebal W, Frick U, Kiipcke W, et al. Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse? Br J Psychiatry 1993; 163 Suppl. 21: 8–21
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962; 10: 799–812
Wing JK, Birley JLT, Cooper JE, et al. Reliability of a procedure for measuring and classifying present psychiatric state. Br J Psychiatry 1967; 113: 499–575
Andreason NC, Olsen SA. Negative versus positive schizophrenia, definition and validation. Arch Gen Psychiatry 1982; 39: 789–94
Kay SR, Opler LA, Fiszbein A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261–76
Awad AG. Methodological and design issues in clinical trials of new neuroleptics — an overview. Br J Psychiatry 1993; 163 Suppl. 22: 51–7
Snaith RP. Measurement in psychiatry. Br J Psychiatry 1991; 159: 78–82
Gerlach J. New anti psychotics: classification, efficacy and adverse effects. Schizophr Bull 1991; 17: 298–309
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Awad, A.G., Voruganti, L.N.P. & Heslegrave, R.J. The Aims of Antipsychotic Medication. CNS Drugs 4, 8–16 (1995). https://doi.org/10.2165/00023210-199504010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199504010-00002